Janney Montgomery Scott LLC Sells 93,748 Shares of Zoetis Inc. $ZTS

Janney Montgomery Scott LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 60.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 62,464 shares of the company’s stock after selling 93,748 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Zoetis were worth $4,489,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ZTS. Prosperity Bancshares Inc bought a new stake in Zoetis during the fourth quarter worth about $25,000. University of Texas Texas AM Investment Management Co. purchased a new stake in Zoetis in the second quarter worth about $25,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis during the first quarter valued at approximately $28,000. Root Financial Partners LLC increased its stake in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new position in shares of Zoetis during the fourth quarter valued at approximately $32,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $73.64 on Friday. The company has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a P/E/G ratio of 1.28 and a beta of 0.74. The business’s fifty day simple moving average is $76.30 and its two-hundred day simple moving average is $99.01. Zoetis Inc. has a 12 month low of $71.45 and a 12 month high of $160.48. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts anticipate that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. Zoetis’s payout ratio is 34.93%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Citigroup dropped their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. JPMorgan Chase & Co. lowered their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Finally, Stifel Nicolaus cut their target price on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, June 26th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $109.62.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.